Bristol-Myers Squibb Firm (NYSE:BMY) is included among the many 12 Greatest Shares to Purchase Now for Passive Earnings.
Bristol-Myers Squibb Firm (NYSE:BMY) is a world biopharmaceutical firm that many take into account price investing in and holding long-term. Its historical past dates again to the early 1800s, formed by a long time of drug innovation and strategic mergers. Right now, the corporate focuses on therapies in oncology, cardiovascular well being, immunology, neuroscience, and blood problems.
In recent times, Bristol-Myers Squibb Firm (NYSE:BMY) has invested roughly $100 billion in acquisitions to arrange for income losses from key medication approaching patent expiration.
Bristol-Myers Squibb Firm (NYSE:BMY) is a powerful dividend firm. On September 17, the corporate declared a quarterly dividend of $0.62 per share, which was consistent with its earlier dividend. Total, it holds a 16-year monitor document of dividend progress, which makes it top-of-the-line shares for passive earnings. As of September 22, the inventory has a dividend yield of 5.51%.
Whereas we acknowledge the potential of BMY as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 12 Greatest Retail Dividend Shares to Purchase Now and 11 Low cost Quarterly Dividend Shares to Purchase Proper Now
Disclosure: None.
![[Vantage Point] A 12 months of reckoning: Which approach, Philippines?](https://www.rappler.com/tachyon/2025/12/vantage-point-a-year-of-reckoning-which-way-philippines-December-27-2025.jpg "[Vantage Point] A 12 months of reckoning: Which approach, Philippines?")
